885523-25-1 Usage
Uses
Used in Pharmaceutical Industry:
4-chloro-6-indazolecarboxylic acid is used as a building block for the synthesis of complex organic molecules, particularly in the development of new pharmaceuticals. Its unique structure allows it to participate in various chemical reactions, making it a valuable component in the creation of novel drug candidates.
Used in Agrochemical Industry:
In the agrochemical sector, 4-chloro-6-indazolecarboxylic acid is utilized as a precursor in the synthesis of compounds with potential pesticidal or herbicidal properties. Its ability to form diverse chemical compounds contributes to the development of new and effective agrochemical products.
Used in Drug Discovery and Development:
4-chloro-6-indazolecarboxylic acid is employed as a potential candidate in drug discovery due to its potential biological activities. Its unique chemical structure may contribute to the development of new therapeutic agents, particularly in the areas where its specific properties can be leveraged for medicinal purposes.
Used in Chemical Synthesis:
4-chloro-6-indazolecarboxylic acid is used as a reactive intermediate in chemical synthesis processes. Its presence of a chlorine atom and carboxylic acid group makes it a versatile component in the formation of a wide array of chemical products, including those with specialized applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 885523-25-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,5,5,2 and 3 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 885523-25:
(8*8)+(7*8)+(6*5)+(5*5)+(4*2)+(3*3)+(2*2)+(1*5)=201
201 % 10 = 1
So 885523-25-1 is a valid CAS Registry Number.
885523-25-1Relevant articles and documents
MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS
-
Paragraph 0486; 0528, (2021/10/15)
The present invention relates to macrocyclic diamine derivatives of formula II, including pharmaceutically acceptable salts and solvates thereof. Compounds of the invention are inhibitors of ENT family transporter, especially of ENT1, and are useful as therapeutic compounds for the treatment of cancers. The invention also relates to the combined use of the macrocyclic diamine derivatives with an adenosine receptor antagonist, for the treatment of cancers.
